Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Receivables (2020 - 2025)

Historic Receivables for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $8.5 million.

  • SOPHiA GENETICS's Receivables fell 1338.86% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 1338.86%. This contributed to the annual value of $7.4 million for FY2024, which is 4515.01% down from last year.
  • Latest data reveals that SOPHiA GENETICS reported Receivables of $8.5 million as of Q3 2025, which was down 1338.86% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, SOPHiA GENETICS's Receivables registered a high of $13.6 million during Q4 2023, and its lowest value of $6.3 million during Q4 2021.
  • Moreover, its 5-year median value for Receivables was $9.0 million (2025), whereas its average is $8.8 million.
  • Per our database at Business Quant, SOPHiA GENETICS's Receivables skyrocketed by 10389.53% in 2023 and then tumbled by 4515.01% in 2024.
  • SOPHiA GENETICS's Receivables (Quarter) stood at $6.3 million in 2021, then increased by 5.91% to $6.6 million in 2022, then surged by 103.9% to $13.6 million in 2023, then plummeted by 45.15% to $7.4 million in 2024, then increased by 13.7% to $8.5 million in 2025.
  • Its Receivables stands at $8.5 million for Q3 2025, versus $9.5 million for Q2 2025 and $10.7 million for Q1 2025.